TRDA

Entrada Therapeutics Inc

TRDA, USA

Entrada Therapeutics, Inc., is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle (EEV")-therapeutics are designed to enable the efficient intracellular delivery of a wide range of therapeutics into a variety of organs and tissues, resulting in an improved therapeutic index. Through this proprietary, versatile and modular approach, Entrada is advancing a robust development portfolio of RNA- and protein-based programmes for the potential treatment of neuromuscular and ocular diseases, among others. The company was formerly known as CycloPorters, Inc., and changed its name to Entrada Therapeutics, Inc., in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.

https://www.entradatx.com

Stock Price

$ 0.00

0% increase compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
TRDA
stock
TRDA

TRDA Stock Analysis and Forecast - Morning Star Patterns & You’ll Thank Yourself in 6 Months earlytimes.in

Read more →
TRDA
stock
TRDA

5AM Venture Management LLC Has $28.95 Million Stake in Entrada Therapeutics, Inc. $TRDA MarketBeat

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

STRONG BUY

Target Price:

$16.5

Analyst Picks

Strong Buy

2

Buy

2

Hold

0

Sell

0

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Very Low

1.35

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

-12.95 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-10.69 %

Low ≤ 2%

High ≥ 10%

Free Cash Flow - Revenue % (FCF)

-

Very Low

-1,764.81 %

Low ≤ 5%

High ≥ 15%

Debt to Equity

-

Very High

0.21

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 90.42% of the total shares of Entrada Therapeutics Inc

1.

Baker Bros Advisors LP

(12.7923%)

since

2025/06/30

2.

Mpm Asset Management, LLC

(11.5179%)

since

2025/06/30

3.

5AM Venture Management, LLC

(11.3268%)

since

2025/06/30

4.

T. Rowe Price Associates, Inc.

(6.7499%)

since

2025/06/30

5.

BlackRock Inc

(5.3163%)

since

2025/06/30

6.

Vanguard Group Inc

(4.2192%)

since

2025/06/30

7.

US Small-Cap Growth II Equity Comp

(4.0026%)

since

2025/06/30

8.

HHG PLC

(3.9995%)

since

2025/06/30

9.

T. Rowe Price New Horizons

(3.5888%)

since

2025/07/31

10.

Wellington Management Company LLP

(2.7886%)

since

2025/06/30

11.

Vanguard Total Stock Mkt Idx Inv

(2.4505%)

since

2025/07/31

12.

StepStone Group LLC

(2.0014%)

since

2025/06/30

13.

iShares Russell 2000 ETF

(1.7374%)

since

2025/08/31

14.

Geode Capital Management, LLC

(1.6604%)

since

2025/06/30

15.

TCG Crossover Management, LLC

(1.5379%)

since

2025/06/30

16.

FMR Inc

(1.3043%)

since

2025/06/30

17.

State Street Corp

(1.3036%)

since

2025/06/30

18.

T. Rowe Price New Horizons Tr-A

(1.2072%)

since

2025/06/30

19.

Dimensional Fund Advisors, Inc.

(1.1147%)

since

2025/06/30

20.

Renaissance Technologies Corp

(0.9977%)

since

2025/06/30

21.

Northern Trust Corp

(0.7895%)

since

2025/06/30

22.

Fidelity Small Cap Index

(0.7353%)

since

2025/06/30

23.

Vanguard Institutional Extnd Mkt Idx Tr

(0.6727%)

since

2025/07/31

24.

iShares Russell 2000 Value ETF

(0.6413%)

since

2025/08/31

25.

Royce & Associates, LP

(0.5869%)

since

2025/06/30

26.

Jacobs Levy Equity Management, Inc.

(0.5803%)

since

2025/06/30

27.

T. Rowe Price Health Sciences

(0.5708%)

since

2025/07/31

28.

Charles Schwab Investment Management Inc

(0.5355%)

since

2025/06/30

29.

Millennium Management LLC

(0.4478%)

since

2025/06/30

30.

Fidelity Growth Compy Commingled Pl S

(0.4311%)

since

2025/07/31

31.

Royce Capital Small-Cap Inv

(0.4014%)

since

2025/06/30

32.

Vanguard Russell 2000 ETF

(0.353%)

since

2025/07/31

33.

iShares Biotechnology ETF

(0.3484%)

since

2025/08/31

34.

Fidelity Extended Market Index

(0.3301%)

since

2025/07/31

35.

Schwab US Small-Cap ETF™

(0.2835%)

since

2025/08/30

36.

Federated Hermes MDT SCC Institutional

(0.2391%)

since

2025/06/30

37.

Federated Hermes MDT Small Cap Core IS

(0.2391%)

since

2025/06/30

38.

DFA US Small Cap Value I

(0.2195%)

since

2025/07/31

39.

State St Russell Sm Cap® Indx SL Cl I

(0.2169%)

since

2025/08/31

40.

Royce Small-Cap Value Service

(0.1856%)

since

2025/06/30

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

—

EPS Estimate

—

Latest Release

Date

2025-09-30

EPS Actual

-1.06

EPS Estimate

-0.9912

EPS Difference

-0.0688

Surprise Percent

-6.9411%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Potential Value Candidate(4.5)
Defensive
Highly Defensive(7)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(4.8)
GARP
Not Attractive for GARP(2.5)
Growth
Weak Growth Prospect(1)
Momentum
Strong Momentum(6.5)
Net Net
Not Undervalued (Net-Net)(2.5)
Quality
Low Quality Business(2.5)
Value
Fair Value(4.5)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.